Table 1.

Patient characteristics.

Cohort	Institution	Patient ID	Age	Gender	Lesion site	IL2 treatment	Patient response
Initial	MSKCC	4	42	M	Skin	Intralesional	CR
Initial	MSKCC	6	74	F	Skin	Intralesional	CR
Initial	MSKCC	0	56	M	Soft tissue	Intralesional	Non-CR
Initial	MSKCC	1	81	F	Skin	Intralesional	Non-CR
Initial	MSKCC	2	67	F	Soft tissue	Intralesional	Non-CR
Initial	MSKCC	3	86	F	Skin	Intralesional	Non-CR
Initial	MSKCC	5	69	M	Skin	Intralesional	Non-CR
Validation	Calgary	v_01	69	F	Skin	Intralesional	CR
Validation	Calgary	v_02	86	F	Skin	Intralesional	CR
Validation	Calgary	v_03	93	M	Skin	Intralesional	CR
Validation	NIH	v_04	52	M	Soft tissue	Systemic	CR
Validation	NIH	v_05	43	M	Skin	Systemic	CR
Validation	NIH	v_06	45	F	Lymph node	Systemic	CR
Validation	NIH	v_07	54	M	Skin	Systemic	Non-CR
Validation	NIH	v_08	63	F	Skin	Systemic	Non-CR
Validation	NIH	v_09	52	M	Soft tissue	Systemic	Non-CR
Validation	NIH	v_10	27	M	Lymph node	Systemic	Non-CR
Validation	NIH	v_11	48	M	Soft tissue	Systemic	Non-CR
Validation	NIH	v_12	48	M	Lung	Systemic	Non-CR
Validation	NIH	v_13	37	M	Lymph node	Systemic	Non-CR
Validation	MDACC	v_14	62	M	Lung	Systemic	Non-CR
Validation	MDACC	v_15	76	F	Skin	Systemic	Non-CR
Validation	MDACC	v_16	65	M	Lymph node	Systemic	Non-CR
Validation	MDACC	v_17	54	M	Lymph node	Systemic	Non-CR
Validation	JHMI	v_18	53	F	Skin	Systemic	Non-CR
Validation	JHMI	v_19	59	M	Skin	Systemic	Non-CR

Note: Clinical information for the metastatic melanoma patients in the initial cohort (n = 7) and in the validation cohort (n = 19) treated with either intralesional IL2 or high-dose systemic IL2. Patient response was classified as complete responder (CR; termed “extreme responder” in the initial cohort) or noncomplete responder (non-CR; termed “non-/mixed responder” in the initial cohort).

Abbreviations: Calgary, University of Calgary; JHMI, Johns Hopkins Medical Institute; MDACC, MD Anderson Cancer Center; MSKCC, Memorial Sloan Kettering Cancer Center; NIH, National Institutes of Health.